Recent Updates
Recently added Catalysts

NG Shield

Phase 2

Intubation, Nasogastric | Unknown | Gastrointestinal |NanoVibronix, Inc.|Last Updated: Mar 25, 2009

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical trial landscape

NG Shield · 1 trial · 1 indication

Phase 2 1
NCT00781248Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube UsageIntubation, Nasogastric
COMPLETED24 Analytics
PHASE2COMPLETED
Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage
Intubation, Nasogastric
NCT0078124824
Unlock trial analytics
Study Endpoints
Primary Endpoints
Pain/discomfort levelusing flicker scale (1-10 scale)during indwelling phase
every 30 minutes for 6 hours
safety of device usage
6 hours
Secondary Endpoints
pain/Dicomfort during insertion and removal of the nasogastric tube
at t=0h and t=6h
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeSUPPORTIVE_CARE
Treatment Arms
ArmTypeDescription
1EXPERIMENTALstarting with active NG Shield
2EXPERIMENTALStarting with inactive NG Shield
Interventions
NameTypeDescription
NG ShieldDEVICEA device to reduce pain/discomfort related to nasogastric tube usage
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Subject is in good health and able to undergoes the NG tube insertion procedure, according to the PI decision 2. Subject is able to understand and answer the pain and discomfort questionnaires 3. Subject has been fasting for at least 12h prior to the insertion phase 4. Subjec...

Countries:Israel
Unlock Eligibility Criteria